SCHEMBL20745310

SCHEMBL20745310

COc1cc(Nc2ccccc2)c(C(=O)O)cc1OC

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.71
ALDH1A1 P00352 2/20 0.71
HPGD P15428 1/20 0.71
NPSR1 Q6W5P4 1/20 0.71
HSD17B10 Q99714 1/20 0.71
RCE1 Q9Y256 1/20 0.71
AKR1C3 P42330 6/20 0.66
AKR1C2 P52895 6/20 0.66
MAPT P10636 4/20 0.61
GFER P55789 2/20 0.61
NGLY1 Q96IV0 1/20 0.61
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
TP53 P04637 1/20 0.56
TSHR P16473 1/20 0.56
CTSV O60911 3/20 0.55
CTSL P07711 3/20 0.55
AKR1C4 P17516 1/20 0.53
AKR1C1 Q04828 1/20 0.53
CYP1A2 P05177 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19260548 0.89 AKR1C3 (0.61) KDM4EALDH1A1HPGDNPSR1HSD17B10
SCHEMBL20745817 0.89 KDM4E (0.65) KDM4EALDH1A1HPGDNPSR1HSD17B10
SCHEMBL1724047 0.88 KDM4E (0.56) KDM4EALDH1A1HPGDNPSR1HSD17B10
SCHEMBL11644754 0.86 AKR1C3 (0.68) KDM4EALDH1A1HPGDNPSR1HSD17B10
SCHEMBL14598923 0.83 AKR1C3 (0.78) HPGDHSD17B10AKR1C3AKR1C2MAPT
SCHEMBL351705 0.82 MAPT (0.79) KDM4EALDH1A1HPGDHSD17B10AKR1C3
SCHEMBL4257100 0.82 MAPT (0.68) KDM4EALDH1A1HPGDNPSR1HSD17B10
SCHEMBL9172301 0.81 MAPT (0.76) KDM4EALDH1A1HPGDHSD17B10AKR1C3
SCHEMBL19260600 0.80 BCHE (0.56) MAPT
SCHEMBL10652538 0.79 AKR1C3 (0.78) HPGDAKR1C3AKR1C2MAPTGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3668863-B1 TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2025-03-19 EP disclosed
US-11661410-B2 Tricyclic compounds as histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-05-30 US disclosed
US-20230002351-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2023-01-05 US disclosed
CN-111372927-A Tricyclic compounds as histone methyltransferase inhibitors 全球血液疗法股份有限公司 2020-07-03 CN disclosed
EP-3668863-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS Global Blood Therapeutics, Inc. (US) 2020-06-24 EP disclosed
WO-2019036377-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2019-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002351-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS EHMT1, EHMT2, BMI1 KDM4E 59/4885ALDH1A1 1652/4885HPGD 3208/4885
US-11661410-B2 Tricyclic compounds as histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 KDM4E 59/4885ALDH1A1 1652/4885HPGD 3208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.